Current costs in AF patients are driven by the consequences of AF, while costs for specific treatments for AF are low. The addition of new, effective and safe treatment options could potentially reduce overall healthcare costs in AF.

: The satisfaction with current AF treatment was low in patients with AF. Physician satisfaction with available AF drugs was driven by efficacy. The same appeared to be true for the patients - satisfaction, compliance, and functional ability would most likely increase with a perceived better drug efficacy.